Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks

Dec 29 2016

• By Michael Cipriano

Bacterias 3D rendering

Related Content

FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway

Feb 11 2013

The Evolution Of 21<sup>st</sup> Century Cures Legislation

Nov 30 2016

Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV

Nov 05 2016

Cempra To Defend CABP Antibiotic's Safety At US FDA Advisory Panel

Nov 03 2016

Rx For Industry: Key Provisions Of The 21<sup>st</sup> Century Cures Act

Dec 09 2016

Related Companies

Melinta Therapeutics, Inc.

Allergan plc

Hospira, Inc.

Pfizer Inc.

Wockhardt Limited

Additional Topics

United States Regulation Complete Response Letters Drug Review BioPharmaceutical Infectious Diseases

More from Complete Response Letters

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window